Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
Abstract
:1. Introduction
1.1. General Considerations on Tumor Immunotherapy
1.2. Nanotechnology and Tumor Immunotherapy
2. Nanoparticles and Hematological Malignancies
2.1. Acute Myeloid Leukemia
2.2. Acute Lymphoblastic Leukemia
2.3. Lymphoma
2.4. Multiple Myeloma
3. Nanoparticles and Chimeric Antigen Receptor-Modified T Cells
4. Tumor Vaccines and Nanoparticles
5. Challenges and Future Perspectives
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Postow, M.A.; Callahan, M.K.; Wolchok, J.D. Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol. 2015, 33, 1974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Phan, G.Q.; Yang, J.C.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Restifo, N.P.; Haworth, L.R.; Seipp, C.A.; Freezer, L.J.; et al. Cancer Regression and Autoimmunity Induced by Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma. Proc. Natl. Acad. Sci. USA 2003, 100, 8372–8377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeil, C.; Kalinka-Warzocha, E.; et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N. Engl. J. Med. 2015, 372, 320–330. [Google Scholar] [CrossRef] [Green Version]
- Byun, D.J.; Wolchok, J.D.; Rosenberg, L.M.; Girotra, M. Cancer Immunotherapy-Immune Checkpoint Blockade and Associated Endocrinopathies. Nat. Rev. Endocrinol. 2017, 13, 195. [Google Scholar] [CrossRef] [Green Version]
- Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell. 2015, 27, 450–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- June, C.H.; Sadelain, M. Chimeric Antigen Receptor Therapy. N. Engl. J. Med. 2018, 379, 64–73. [Google Scholar] [CrossRef] [PubMed]
- DePriest, B.P.; Vieira, N.; Bidgoli, A.; Paczesny, S. An overview of multiplexed analyses of CAR T-cell therapies: Insights and potential. Expert Rev Proteomics. 2021, 1–14. [Google Scholar] [CrossRef]
- Baeuerle, P.A.; Kufer, P.; Bargou, R. BiTE: Teaching Antibodies to Engage T-Cells for Cancer Therapy. Curr. Opin. Mol. Ther. 2009, 11, 22–30. [Google Scholar]
- Huehls, A.M.; Coupet, T.A.; Sentman, C.L. Bispecific T-Cell Engagers for Cancer Immunotherapy. Immunol. Cell Biol. 2015, 93, 290–296. [Google Scholar] [CrossRef] [Green Version]
- Kantarjian, H.; Stein, A.; Gökbuget, N.; Fielding, A.K.; Schuh, A.C.; Ribera, J.-M.; Wei, A.; Dombret, H.; Foà, R.; Bassan, R.; et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2017, 376, 836–847. [Google Scholar] [CrossRef]
- Raje, N.; Berdeja, J.; Lin, Y.; Siegel, D.; Jagannath, S.; Madduri, D.; Liedtke, M.; Rosenblatt, J.; Maus, M.V.; Turka, A.; et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2019, 380, 1726–1737. [Google Scholar] [CrossRef]
- Bansal, R.; Jurcic, J.G.; Sawas, A.; Mapara, M.Y.; Reshef, R. Chimeric Antigen Receptor T Cells for Treatment of Transformed Waldenström Macroglobulinemia. Leuk. Lymphoma 2020, 61, 465–468. [Google Scholar] [CrossRef] [PubMed]
- Drake, C.G.; Lipson, E.J.; Brahmer, J.R. Breathing New Life into Immunotherapy: Review of Melanoma, Lung and Kidney cancer. Nat. Rev. Clin. Oncol. 2014, 11, 24–37. [Google Scholar] [CrossRef]
- Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015, 373, 1803–1813. [Google Scholar] [CrossRef] [PubMed]
- Park, W.; Heo, Y.J.; Han, D.K. New Opportunities for Nanoparticles in Cancer Immunotherapy. Biomater. Res. 2018, 22, 24. [Google Scholar] [CrossRef] [Green Version]
- Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 372, 2018–2028. [Google Scholar] [CrossRef]
- Nghiem, P.T.; Bhatia, S.; Lipson, E.J.; Kudchadkar, R.R.; Miller, N.J.; Annamalai, L.; Berry, S.; Chartash, E.K.; Daud, A.; Fling, S.P.; et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N. Engl. J. Med. 2016, 374, 2542–2552. [Google Scholar] [CrossRef]
- Pardoll, D. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. [Google Scholar] [CrossRef] [Green Version]
- Weigert, A.; Brüne, B. Nitric Oxide, Apoptosis and Macrophage Polarization during Tumor Progression. Nitric Oxide 2008, 19, 95–102. [Google Scholar] [CrossRef] [PubMed]
- Nesbit, M.; Schaider, H.; Miller, T.H.; Herlyn, M. Low-Level Monocyte Chemoattractant Protein-1 Stimulation of Monocytes Leads to Tumor Formation in Nontumorigenic Melanoma Cells. J. Immunol. 2001, 166, 6483–6490. [Google Scholar] [CrossRef] [Green Version]
- Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of Tumor-Associated Macrophages in Tumor Progression and Invasion. Cancer Metastasis Rev. 2006, 25, 315–322. [Google Scholar] [CrossRef]
- Ostrand-Rosenberg, S. Tolerance and Immune Suppression in the Tumor Microenvironment. Cell. Immunol. 2016, 299, 23–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Musolino, C.; Allegra, A.; Pioggia, G.; Gangemi, S. Immature Myeloid-Derived Suppressor Cells: A Bridge between Inflammation and Cancer (Review). Oncol. Rep. 2017, 37, 671–683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lu, R.; Turan, T.; Samayoa, J.; Marincola, F.M. Cancer Immune Resistance: Can Theories Converge? Emerg. Top. Life Sci. 2017, 1, 411–419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Turan, T.; Kannan, D.; Patel, M.; Matthew Barnes, J.; Tanlimco, S.G.; Lu, R.; Halliwill, K.; Kongpachith, S.; Kline, D.E.; Hendrickx, W.; et al. Immune Oncology, Immune Responsiveness and the Theory of Everything. J. Immunother. Cancer 2018, 6, 50. [Google Scholar] [CrossRef] [Green Version]
- Wang, E.; Worschech, A.; Marincola, F.M. The Immunologic Constant of Rejection. Trends Immunol. 2008, 29, 256–262. [Google Scholar] [CrossRef]
- Hendrickx, W.; Simeone, I.; Anjum, S.; Mokrab, Y.; Bertucci, F.; Finetti, P.; Curigliano, G.; Seliger, B.; Cerulo, L.; Tomei, S.; et al. Identification of Genetic Determinants of Breast Cancer Immune Phenotypes by Integrative Genome-Scale Analysis. Oncoimmunology 2017, 6, e1253654. [Google Scholar] [CrossRef] [Green Version]
- Galon, J.; Angell, H.K.; Bedognetti, D.; Marincola, F.M. The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity 2013, 39, 11–26. [Google Scholar] [CrossRef] [Green Version]
- Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome. Science 2006, 313, 1960–1964. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Camus, M.; Tosolini, M.; Mlecnik, B.; Pages, F.; Kirilovsky, A.; Berger, A.; Costes, A.; Bindea, G.; Charoentong, P.; Bruneval, P.; et al. Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence. Cancer Res. 2009, 69, 2685–2693. [Google Scholar] [CrossRef] [Green Version]
- Roth, P.; Winklhofer, S.; Müller, A.M.S.; Dummer, R.; Mair, M.J.; Gramatzki, D.; Le Rhun, E.; Manz, M.G.; Weller, M.; Preusser, M. Neurological Complications of Cancer Immunotherapy. Cancer Treat. Rev. 2021, 97, 102189. [Google Scholar] [CrossRef] [PubMed]
- Rubin, D.B.; Vaitkevicius, H. Neurological Complications of Cancer Immunotherapy (CAR T Cells). J. Neurol. Sci. 2021, 424, 117405. [Google Scholar] [CrossRef]
- Allegra, A.; Penna, G.; Alonci, A.; Rizzo, V.; Russo, S.; Musolino, C. Nanoparticles in Oncology: The New Theragnostic Molecules. Anti-Cancer Agents Med. Chem. 2011, 11, 669–686. [Google Scholar] [CrossRef]
- Overchuk, M.; Zheng, G. Overcoming Obstacles in the Tumor Microenvironment: Recent Advancements in Nanoparticle Delivery for Cancer Theranostics. Biomaterials 2018, 156, 217–237. [Google Scholar] [CrossRef]
- Lammers, T.; Kiessling, F.; Hennink, W.E.; Storm, G. Drug Targeting to Tumors: Principles, Pitfalls and (Pre-) Clinical Progress. J. Control. Release 2012, 161, 175–187. [Google Scholar] [CrossRef]
- Loomis, K.; Smith, B.; Feng, Y.; Garg, H.; Yavlovich, A.; Campbell-Massa, R.; Dimitrov, D.S.; Blumenthal, R.; Xiao, X.; Puri, A. Specific Targeting to B Cells by Lipid-Based Nanoparticles Conjugated with a Novel CD22-ScFv. Exp. Mol. Pathol. 2010, 88, 238–249. [Google Scholar] [CrossRef] [Green Version]
- Tuscano, J.M.; Martin, S.M.; Ma, Y.; Zamboni, W.; O’Donnell, R.T. Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-Cell Non-Hodgkin’s Lymphoma Xenograft Mouse Model. Clin. Cancer Res. 2010, 16, 2760–2768. [Google Scholar] [CrossRef] [Green Version]
- Chen, W.C.; Completo, G.C.; Sigal, D.S.; Crocker, P.R.; Saven, A.; Paulson, J.C. In Vivo Targeting of B-Cell Lymphoma with Glycan Ligands of CD22. Blood 2010, 115, 4778–4786. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsumura, Y.; Maeda, H. A New Concept for macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986, 46, 6387–6392. [Google Scholar] [PubMed]
- Prabhakar, U.; Maeda, H.; Jain, R.K.; Sevick-Muraca, E.M.; Zamboni, W.; Farokhzad, O.C.; Barry, S.T.; Gabizon, A.; Grodzinski, P.; Blakey, D.C. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology. Cancer Res. 2013, 73, 2412–2417. [Google Scholar] [CrossRef] [Green Version]
- Muntimadugu, E.; Kommineni, N.; Khan, W. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy. Pharmacol. Res. 2017, 126, 109–122. [Google Scholar] [CrossRef]
- Barenholz, Y. Doxil®-The First FDA-Approved Nano-Drug: Lessons Learned. J. Control. Release 2012, 160, 117–134. [Google Scholar] [CrossRef]
- Yasuno, G.; Koide, H.; Oku, N.; Asai, T. Influence of Purification Process on the Function of Synthetic Polymer Nanoparticles. Chem. Pharm. Bull. 2021, 69, 773–780. [Google Scholar] [CrossRef]
- Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, Preparation, and Applications. Nanoscale Res. Lett. 2013, 8, 102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abbasi, E.; Aval, S.F.; Akbarzadeh, A.; Milani, M.; Nasrabadi, H.T.; Joo, S.W.; Hanifehpour, Y.; Nejati-Koshki, K.; Pashaei-Asl, R. Dendrimers: Synthesis, applications, and properties. Nanoscale Res. Lett. 2014, 9, 247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Madaan, K.; Kumar, S.; Poonia, N.; Lather, V.; Pandita, D. Dendrimers in Drug Delivery and Targeting: Drug-Dendrimer Interactions and Toxicity Issues. J. Pharm. BioAllied Sci. 2014, 6, 139–150. [Google Scholar] [PubMed]
- Kim, H.; Beack, S.; Han, S.; Shin, M.; Lee, T.; Park, Y.; Kim, K.S.; Yetisen, A.K.; Yun, S.H.; Kwon, W.; et al. Multifunctional Photonic Nanomaterials for Diagnostic, Therapeutic, and Theranostic Applications. Adv. Mater. 2018, 30, 1701460. [Google Scholar] [CrossRef]
- Lee, M.-Y.; Lee, C.; Jung, H.S.; Jeon, M.; Kim, K.S.; Yun, S.H.; Kim, C.; Hahn, S.K. Biodegradable Photonic Melanoidin for Theranostic Applications. ACS Nano 2016, 10, 822–831. [Google Scholar] [CrossRef] [PubMed]
- Cha, C.; Shin, S.R.; Annabi, N.; Dokmeci, M.R.; Khademhosseini, A. Carbon-Based Nanomaterials: Multifunctional Materials for Biomedical Engineering. ACS Nano 2013, 7, 2891–2897. [Google Scholar] [CrossRef]
- Zhang, X. Gold Nanoparticles: Recent Advances in the Biomedical Applications. Cell Biochem. Biophys. 2015, 72, 771–775. [Google Scholar] [CrossRef]
- Baffou, G.; Quidant, R. Thermo-Plasmonics: Using Metallic Nanostructures as Nano-Sources of Heat. Laser Photon. Rev. 2013, 7, 171–187. [Google Scholar] [CrossRef]
- Kim, H.; Park, Y.; Stevens, M.M.; Kwon, W.; Hahn, S.K. Multifunctional Hyaluronate-Nanoparticle Hybrid Systems for Diagnostic, Therapeutic and Theranostic Applications. J. Control. Release 2019, 303, 55–66. [Google Scholar] [CrossRef] [PubMed]
- Yau, A.; Lee, J.; Chen, Y. Nanomaterials for Protein Delivery in Anticancer Applications. Pharmaceutics 2021, 13, 155. [Google Scholar] [CrossRef] [PubMed]
- Rahimian, S.; Fransen, M.F.; Kleinovink, J.W.; Amidi, M.; Ossendorp, F.; Hennink, W.E. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer. Curr. Pharm. Des. 2015, 21, 4201–4216. [Google Scholar] [CrossRef]
- Vermonden, T.; Censi, R.; Hennink, W.E. Hydrogels for Protein Delivery. Chem. Rev. 2012, 112, 2853–2888. [Google Scholar] [CrossRef]
- Soetaert, F.; Korangath, P.; Serantes, D.; Fiering, S.; Ivkov, R. Cancer Therapy with Iron Oxide Nanoparticles: Agents of Thermal and Immune Therapies. Adv. Drug Deliv. Rev. 2020, 163, 65–83. [Google Scholar] [CrossRef]
- Liu, X.; Yan, B.; Li, Y.; Ma, X.; Jiao, W.; Shi, K.; Zhang, T.; Chen, S.; He, Y.; Liang, X.J.; et al. Graphene Oxide-Grafted Magnetic Nanorings Mediated Magneto Thermodynamic Therapy Favoring Reactive Oxygen Species-Related Immune Response for Enhanced Antitumor Efficacy. ACS Nano 2020, 14, 1936–1950. [Google Scholar] [CrossRef]
- Zhao, Y.; Zhao, X.; Cheng, Y.; Guo, X.; Yuan, W. Iron Oxide Nanoparticles-Based Vaccine Delivery for Cancer Treatment. Mol. Pharm. 2018, 15, 1791–1799. [Google Scholar] [CrossRef] [PubMed]
- Wang, B.; An, J.; Zhang, H.; Zhang, S.; Zhang, H.; Wang, L.; Zhang, H.; Zhang, Z. Personalized Cancer Immunotherapy via Transporting Endogenous Tumor Antigens to Lymph Nodes Mediated by Nano Fe3O4. Small 2018, 14, e1801372. [Google Scholar] [CrossRef]
- Chao, Y.; Chen, G.; Liang, C.; Xu, J.; Dong, Z.; Han, X.; Wang, C.; Liu, Z. Iron Nanoparticles for Low-Power Local Magnetic Hyperthermia in Combination with Immune Checkpoint Blockade for Systemic Antitumor Therapy. Nano Lett. 2019, 19, 4287–4296. [Google Scholar] [CrossRef]
- Yang, S.; Gao, H. Nanoparticles for Modulating Tumor Microenvironment to Improve Drug Delivery and Tumor Therapy. Pharmacol. Res. 2017, 126, 97–108. [Google Scholar] [CrossRef]
- Chen, Q.; Liu, G.; Liu, S.; Su, H.; Wang, Y.; Li, J.; Luo, C. Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics. Trends Pharmacol. Sci. 2018, 39, 59–74. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Zhang, F.; Su, Y.; Zhou, J.; Wang, W. Nanoparticles Designed to Regulate Tumor Microenvironment for Cancer Therapy. Life Sci. 2018, 201, 37–44. [Google Scholar] [CrossRef] [PubMed]
- Irvine, D.J.; Hanson, M.C.; Rakhra, K.; Tokatlian, T. Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem. Rev. 2015, 115, 11109–11146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, C.; Ye, Y.; Hu, Q.; Bellotti, A.; Gu, Z. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. Adv Mater. 2017, 29. [Google Scholar] [CrossRef] [PubMed]
- Constantino, J.; Gomes, C.; Falcao, A.; Neves, B.M.; Cruz, M.T. Dendritic Cell-Based Immunotherapy: A Basic Review and Recent Advances. Immunol. Res. 2017, 65, 798–810. [Google Scholar] [CrossRef]
- Gardner, A.; Ruffell, B. Dendritic Cells and Cancer Immunity. Trends Immunol. 2016, 37, 855–865. [Google Scholar] [CrossRef] [Green Version]
- Doedens, A.L.; Stockmann, C.; Rubinstein, M.P.; Liao, D.; Zhang, N.; DeNardo, D.G.; Coussens, L.M.; Karin, M.; Goldrath, A.W.; Johnson, R.S. Macrophage Expression of Hypoxia-Inducible Factor-1 Alpha Suppresses T-Cell Function and Promotes Tumor Progression. Cancer Res. 2010, 70, 7465–7475. [Google Scholar] [CrossRef] [Green Version]
- Colegio, O.R.; Chu, N.Q.; Szabo, A.L.; Chu, T.; Rhebergen, A.M.; Jairam, V.; Cyrus, N.; Brokowski, C.E.; Eisenbarth, S.C.; Phillips, G.M.; et al. Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid. Nature 2014, 513, 559–563. [Google Scholar] [CrossRef]
- Joshi, M.D.; Unger, W.J.; Storm, G.; Kooyk, Y.; Mastrobattista, E. Targeting Tumor Antigens to Dendritic Cells Using Particulate Carriers. J. Control. Release 2012, 161, 25–37. [Google Scholar] [CrossRef]
- Dominguez, A.L.; Lustgarten, J. Targeting the Tumor Microenvironment with Anti-Neu/Anti-CD40 Conjugated Nanoparticles for the Induction of Antitumor Immune Responses. Vaccine 2010, 28, 1383–1390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosalia, R.A.; Cruz, L.J.; Duikeren, S.; Tromp, T.; Silva, A.L.; Jiskoot, W.; Gruijl, T.; Lowik, C.; Oostendorp, J.; Burg, S.H.; et al. CD40-Targeted Dendritic Cell Delivery of PLGA-Nanoparticle Vaccines Induce Potent Anti-Tumor Responses. Biomaterials 2015, 40, 88–97. [Google Scholar] [CrossRef] [PubMed]
- Cruz, L.J.; Rosalia, R.A.; Kleinovink, J.W.; Rueda, F.; Lowik, C.W.; Ossendorp, F. Targeting Nanoparticles to CD40, DEC-205 or CD11c Molecules on Dendritic Cells for Efficient CD8(+) T Cell Response: A Comparative Study. J. Control. Release 2014, 192, 209–218. [Google Scholar] [CrossRef] [PubMed]
- Shekarian, T.; Valsesia-Wittmann, S.; Brody, J.; Michallet, M.C.; Depil, S.; Caux, C.; Marabelle, A. Pattern Recognition Receptors: Immune Targets to Enhance Cancer Immunotherapy. Ann. Oncol. 2017, 28, 1756–1766. [Google Scholar] [CrossRef] [PubMed]
- Wilson, J.T.; Keller, S.; Manganiello, M.J.; Cheng, C.; Lee, C.C.; Opara, C.; Convertine, A.; Stayton, P.S. pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides. ACS Nano 2013, 7, 3912–3925. [Google Scholar] [CrossRef] [PubMed]
- Hanson, M.C.; Crespo, M.P.; Abraham, W.; Moynihan, K.D.; Szeto, G.L.; Chen, S.H.; Melo, M.B.; Mueller, S.; Irvine, D.J. Nanoparticulate STING Agonists Are Potent Lymph Node-Targeted Vaccine Adjuvants. J. Clin. Investig. 2015, 125, 2532–2546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, S.; Zhang, H.; Shi, X.; Wu, H.; Hanagata, N. Microfluidic Generation of Chitosan/CpG Oligodeoxynucleotide Nanoparticles with Enhanced Cellular Uptake and Immunostimulatory Properties. Lab Chip 2014, 14, 1842–1849. [Google Scholar] [CrossRef] [PubMed]
- Luo, M.; Wang, H.; Wang, Z.; Cai, H.; Lu, Z.; Li, Y.; Du, M.; Huang, G.; Wang, C.; Chen, X.; et al. A STING-Activating Nanovaccine for Cancer Immunotherapy. Nat. Nanotechnol. 2017, 12, 648–654. [Google Scholar] [CrossRef]
- Yang, M.; Li, J.; Gu, P.; Fan, X. The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment. Bioact. Mater. 2020, 6, 1973–1987. [Google Scholar] [CrossRef]
- Zhang, L.X.; Xie, X.X.; Liu, D.Q.; Xu, Z.P.; Liu, R.T. Efficient Co-Delivery of Neo-Epitopes Using Dispersion-Stable Layered Double Hydroxide Nanoparticles for Enhanced Melanoma Immunotherapy. Biomaterials 2018, 174, 54–66. [Google Scholar] [CrossRef]
- Tran, T.H.; Tran, T.T.P.; Nguyen, H.T.; Phung, C.D.; Jeong, J.H.; Stenzel, M.H.; Jin, S.G.; Yong, C.S.; Truong, D.H.; Kim, J.O. Nanoparticles for Dendritic Cell-Based Immunotherapy. Int. J. Pharm. 2018, 542, 253–265. [Google Scholar] [CrossRef]
- Chen, J.; Kao, Y.R.; Sun, D.; Todorova, T.I.; Reynolds, D.; Narayanagari, S.R.; Montagna, C.; Will, B.; Verma, A.; Steidl, U. Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level. Nat. Med. 2019, 25, 103–110. [Google Scholar] [CrossRef]
- Daver, N.; Garcia-Manero, G.; Basu, S.; Boddu, P.C.; Alfayez, M.; Cortes, J.E.; Konopleva, M.; Ravandi-Kashani, F.; Jabbour, E.; Kadia, T.; et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019, 9, 370–383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yong, S.B.; Kim, J.; Chung, J.Y.; Ra, S.; Kim, S.S.; Kim, Y.H. Heme Oxygenase 1-Targeted Hybrid Nanoparticle for Chemo- and Immuno-Combination Therapy in Acute Myelogenous Leukemia. Adv. Sci. 2020, 7, 2000487. [Google Scholar] [CrossRef] [PubMed]
- Hughes, B. Antibody-Drug Conjugates for Cancer: Poised to Deliver? Nat. Rev. Drug Discov. 2010, 9, 665. [Google Scholar] [CrossRef] [PubMed]
- Mannargudi, M.B.; Deb, S. Clinical Pharmacology and Clinical Trials of Ribonucleotide Reductase Inhibitors: Is It a Viable Cancer Therapy? J. Cancer Res. Clin. Oncol. 2017, 143, 1499–1529. [Google Scholar] [CrossRef]
- Kirschbaum, M.H.; Frankel, P.; Synold, T.W.; Xie, Z.; Yen, Y.; Popplewell, L.; Chen, R.; Aljitawi, O.; Tuscano, J.M.; Chan, K.K.; et al. A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study. Leuk. Lymphoma 2016, 57, 2307–2314. [Google Scholar] [CrossRef] [Green Version]
- Li, H.; Xu, S.; Quan, J.; Yung, B.C.; Pang, J.; Zhou, C.; Cho, Y.A.; Zhang, M.; Liu, S.; Muthusamy, N.; et al. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. Mol. Pharm. 2015, 12, 2010–2018. [Google Scholar] [CrossRef] [Green Version]
- Chandran, P.; Gupta, N.; Retnakumari, A.P.; Malarvizhi, G.L.; Keechilat, P.; Nair, S.; Koyakutty, M. Simultaneous Inhibition of Aberrant Cancer Kinome using Rationally Designed Polymer-Protein Core-Shell Nanomedicine. Nanomedicine 2013, 9, 1317–1327. [Google Scholar] [CrossRef]
- Suarez, L.; Wang, R.; Carmer, S.; Bednarik, D.; Myint, H.; Jones, K.; Oelke, M. AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties. Transfus. Med. Hemother. 2020, 47, 464–471. [Google Scholar] [CrossRef]
- Pui, C.H.; Jeha, S. New Therapeutic Strategies for the Treatment of Acute Lymphoblastic Leukaemia. Nat. Rev. Drug Discov. 2007, 6, 149–165. [Google Scholar] [CrossRef] [PubMed]
- Tatar, A.S.; Nagy-Simon, T.; Tomuleasa, C.; Boca, S.; Astilean, S. Nanomedicine Approaches in Acute Lymphoblastic Leukemia. J. Control. Release 2016, 238, 123–138. [Google Scholar] [CrossRef]
- Harata, M.; Soda, Y.; Tani, K.; Ooi, J.; Takizawa, T.; Chen, M.; Bai, Y.; Izawa, K.; Kobayashi, S.; Tomonari, A.; et al. CD19-Targeting Liposomes Containing Imatinib Efficiently Kill Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cells. Blood 2004, 104, 1442–1449. [Google Scholar] [CrossRef] [PubMed]
- Tatar, A.S.; Jurj, A.; Tomuleasa, C.; Florea, A.; Berindan-Neagoe, I.; Cialla-May, D.; Popp, J.; Astilean, S.; Boca, S. CD19-Targeted, Raman Tagged Gold Nanourchins as Theranostic Agents against Acute Lymphoblastic Leukemia. Colloids Surf. B Biointerfaces 2019, 184, 110478. [Google Scholar] [CrossRef] [PubMed]
- Krishnan, V.; Xu, X.; Kelly, D.; Snook, A.; Waldman, S.A.; Mason, R.W.; Jia, X.; Rajasekaran, A.K. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. Mol. Pharm. 2015, 12, 2101–2121. [Google Scholar] [CrossRef] [Green Version]
- Dinauer, N.; Balthasar, S.; Weber, C.; Kreuter, J.; Langer, K.; von Briesen, H. Selective Targeting of Antibody-Conjugated Nanoparticles to Leukemic Cells and Primary T-Lymphocytes. Biomaterials 2005, 26, 5898–5906. [Google Scholar] [CrossRef]
- Brito, A.E.M.; Pessoa, A., Jr.; Converti, A.; Rangel-Yagui, C.O.; Silva, J.A.D.; Apolinário, A.C. Poly (Lactic-Co-Glycolic Acid) Nanospheres Allow for High l-Asparaginase Encapsulation Yield and Activity. Mater. Sci. Eng. C 2019, 98, 524–534. [Google Scholar] [CrossRef]
- Smith, J.D.; Cardwell, L.N.; Porciani, D.; Nguyen, J.A.; Zhang, R.; Gallazzi, F.; Tata, R.R.; Burke, D.H.; Daniels, M.A.; Ulery, B.D. Aptamer-Displaying Peptide Amphiphile Micelles as a Cell-Targeted Delivery Vehicle of Peptide Cargoes. Phys. Biol. 2018, 15, 065006. [Google Scholar] [CrossRef]
- Bahreyni, A.; Yazdian-Robati, R.; Ramezani, M.; Rasouli, M.; Alinezhad Nameghi, M.; Alibolandi, M.; Abnous, K.; Taghdisi, S.M. Identification and Imaging of Leukemia Cells Using Dual-Aptamer-Functionalized Graphene Oxide Complex. J. Biomater. Appl. 2017, 32, 74–81. [Google Scholar] [CrossRef]
- Ocsoy, I.; Gulbakan, B.; Shukoor, M.I.; Xiong, X.; Chen, T.; Powell, D.H.; Tan, W. Aptamer-Conjugated Multifunctional Nanoflowers as a Platform for Targeting, Capture, and Detection in Laser Desorption Ionization Mass Spectrometry. ACS Nano 2013, 7, 417–427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagy-Simon, T.; Tatar, A.S.; Craciun, A.M.; Vulpoi, A.; Jurj, M.A.; Florea, A.; Tomuleasa, C.; Berindan-Neagoe, I.; Astilean, S.; Boca, S. Antibody Conjugated, Raman Tagged Hollow Gold-Silver Nanospheres for Specific Targeting and Multimodal Dark-Field/SERS/Two Photon-FLIM Imaging of CD19(+) B Lymphoblasts. ACS Appl. Mater. Interfaces 2017, 9, 21155–21168. [Google Scholar] [CrossRef]
- Danesh, N.M.; Lavaee, P.; Ramezani, M.; Abnous, K.; Taghdisi, S.M. Targeted and Controlled Release Delivery of Daunorubicin to T-Cell Acute Lymphoblastic Leukemia by Aptamer-Modified Gold Nanoparticles. Int. J. Pharm. 2015, 489, 311–317. [Google Scholar] [CrossRef] [PubMed]
- Silverman, J.A.; Reynolds, L.; Deitcher, S.R. Pharmacokinetics and Pharmacodynamics of Vincristine Sulfate Liposome Injection (VSLI) in Adults with Acute Lymphoblastic Leukemia. J. Clin. Pharmacol. 2013, 53, 1139–1145. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, S.; Schiller, G.; Lister, J.; Damon, L.; Goldberg, S.; Aulitzky, W.; Ben-Yehuda, D.; Stock, W.; Coutre, S.; Douer, D.; et al. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2013, 31, 676–683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanaka, J. Recent Advances in Cellular Therapy for Malignant Lymphoma. Cytotherapy 2021, 23, 662–671. [Google Scholar] [CrossRef]
- Engelhard, M. Anti-CD20 Antibody Treatment of Non-Hodgkin Lymphomas. Clin. Immunol. 2016, 172, 101–104. [Google Scholar] [CrossRef]
- Johnson, N.A.; Boyle, M.; Bashashati, A.; Leach, S.; Brooks-Wilson, A.; Sehn, L.H.; Chhanabhai, M.; Brinkman, R.R.; Connors, J.M.; Weng, A.P.; et al. Diffuse Large B-Cell Lymphoma: Reduced CD20 Expression is Associated with an Inferior Survival. Blood 2009, 113, 3773–3780. [Google Scholar] [CrossRef] [Green Version]
- Perez-Callejo, D.; Gonzalez-Rincon, J.; Sanchez, A.; Provencio, M.; Sanchez-Beato, M. Action and Resistance of Monoclonal CD20 Antibodies Therapy in B-Cell Non-Hodgkin Lymphomas. Cancer Treat. Rev. 2015, 41, 680–689. [Google Scholar] [CrossRef]
- Davis, T.A.; Czerwinski, D.K.; Levy, R. Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression. Clin. Cancer Res. 1999, 5, 611–615. [Google Scholar]
- Wang, K.; Wei, G.; Liu, D. CD19: A Biomarker for B Cell Development, Lymphoma Diagnosis and Therapy. Exp. Hematol. Oncol. 2012, 1, 36. [Google Scholar] [CrossRef] [Green Version]
- Naddafi, F.; Davami, F. Anti-CD19 Monoclonal Antibodies: A New Approach to Lymphoma Therapy. Int. J. Mol. Cell. Med. 2015, 4, 143–151. [Google Scholar] [PubMed]
- Lee, S.J.; Kim, J.J.; Kang, K.Y.; Paik, M.J.; Lee, G.; Yee, S.T. Enhanced Anti-Tumor Immunotherapy by Silica-Coated Magnetic Nanoparticles Conjugated with Ovalbumin. Int. J. Nanomed. 2019, 14, 8235–8249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhai, Q.; Chen, Y.; Xu, J.; Huang, Y.; Sun, J.; Liu, Y.; Zhang, X.; Li, S.; Tang, S. Lymphoma Immunochemotherapy: Targeted Delivery of Doxorubicin via a Dual Functional Nanocarrier. Mol. Pharm. 2017, 14, 3888–3895. [Google Scholar] [CrossRef]
- Wi, T.I.; Byeon, Y.; Won, J.E.; Lee, J.M.; Kang, T.H.; Lee, J.W.; Lee, Y.J.; Sood, A.K.; Han, H.D.; Park, Y.M. Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-Lactide-co-Glycolide) Nanoparticles for Cancer Immunotherapy. J. Biomed. Nanotechnol. 2020, 16, 201–211. [Google Scholar] [CrossRef] [PubMed]
- Rochman, Y.; Spolski, R.; Leonard, W.J. New Insights into the Regulation of T Cells by γc Family Cytokines. Nat. Rev. Immunol. 2009, 9, 480–490. [Google Scholar] [CrossRef]
- Toyota, H.; Yanase, N.; Yoshimoto, T.; Harada, M.; Kato, Y.; Mizuguchi, J. Vaccination with OVA-Bound Nanoparticles Encapsulating IL-7 Inhibits the Growth of OVA-Expressing E.G7 Tumor Cells In Vivo. Oncol. Rep. 2015, 33, 292–296. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.; Li, H.; Zhao, H.; Zhang, W.; Chen, Y.; Yue, Z.; Lu, Q.; Wan, Y.; Tian, X.; Deng, A. Potentiating Antilymphoma Efficacy of Chemotherapy Using a Liposome for Integration of CD20 Targeting, Ultra-Violet Irradiation Polymerizing, and Controlled Drug Delivery. Nanoscale Res. Lett. 2014, 9, 447. [Google Scholar] [CrossRef] [Green Version]
- Bai, C.; Hu, P.; Zhang, W.; Song, L.; Liu, D.; Chen, Y.; Ma, M.; Gu, N.; Zhang, Y. Modular Design of Bi-Specific Nanoplatform Engaged in Malignant Lymphoma Immunotherapy. Nanoscale 2020, 12, 18418–18428. [Google Scholar] [CrossRef]
- Mezzaroba, N.; Zorzet, S.; Secco, E.; Biffi, S.; Tripodo, C.; Calvaruso, M.; Mendoza-Maldonado, R.; Capolla, S.; Granzotto, M.; Spretz, R.; et al. New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. PLoS ONE 2013, 8, e74216. [Google Scholar] [CrossRef]
- Goyal, S.; Oak, E.; Luo, J.; Cashen, A.F.; Carson, K.; Fehniger, T.; DiPersio, J.; Bartlett, N.L.; Wagner-Johnston, N.D. Minimal Activity of Nanoparticle Albumin-Bound (Nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study. Leuk. Lymphoma 2018, 59, 357–362. [Google Scholar] [CrossRef] [PubMed]
- Van der Zee, J. Heating the Patient: A Promising Approach? Ann. Oncol. 2002, 13, 1173–1184. [Google Scholar] [CrossRef]
- Geehan, D.M.; Fabian, D.F.; Lefor, A.T. Combined Local Hyperthermia and Immunotherapy Treatment of an Experimental Subcutaneous Murine Melanoma. J. Surg. Oncol. 1995, 59, 35–39. [Google Scholar] [CrossRef]
- Anjum, A.; Fleischmann, W.R., Jr. Effect of Hyperthermia on the Antitumor Actions of Interferons. J. Biol. Regul. Homeost. Agents 1992, 6, 75–86. [Google Scholar]
- Mise, K.; Kan, N.; Okino, T.; Nakanishi, M.; Satoh, K.; Teranuma, Y.; Yamasaki, S.; Ohgaki, K.; Tobe, T. Effect of Heat Treatment on Tumor Cells and Antitumor Effector Cells. Cancer Res. 1990, 50, 6199–6202. [Google Scholar] [PubMed]
- Mondovi, B.; Santoro, A.S.; Strom, R.; Faiola, R.; Fanelli, A.R. Increased Immunogenicity of Ehrlich Ascites Cells after Heat Treatment. Cancer 1972, 30, 885–888. [Google Scholar] [CrossRef]
- Ito, A.; Shinkai, M.; Honda, H.; Yoshikawa, K.; Saga, S.; Wakabayashi, T.; Yoshida, J.; Kobayashi, T. Heat Shock Protein 70 Expression Induces Antitumor Immunity during Intracellular Hyperthermia Using Magnetite Nanoparticles. Cancer Immunol. Immunother. 2003, 52, 80–88. [Google Scholar] [CrossRef]
- Ito, A.; Tanaka, K.; Kondo, M.; Shinkai, M.; Honda, H.; Matsumoto, K.; Saida, T.; Kobayashi, T. Tumor Regression by Combined Immunotherapy and Hyperthermia Using Magnetic Nanoparticles in an Experimental Subcutaneous Murine Melanoma. Cancer Sci. 2003, 94, 308–313. [Google Scholar] [CrossRef] [PubMed]
- Shinkai, M.; Yanase, M.; Honda, H.; Wakabayashi, T.; Yoshida, J.; Kobayashi, T. Intracellular Hyperthermia for Cancer Using Magnetite Cationic Liposomes: In Vitro Study. Jpn. J. Cancer Res. 1996, 87, 1179–1183. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, K.; Ito, A.; Kobayashi, T.; Kawamura, T.; Shimada, S.; Matsumoto, K.; Saida, T.; Honda, H. Heat Immunotherapy Using Magnetic Nanoparticles and Dendritic Cells for T-Lymphoma. J. Biosci. Bioeng. 2005, 100, 112–115. [Google Scholar] [CrossRef]
- Allegra, A.; Pioggia, G.; Tonacci, A.; Musolino, C.; Gangemi, S. Oxidative Stress and Photodynamic Therapy of Skin Cancers: Mechanisms, Challenges and Promising Developments. Antioxidants 2020, 9, 448. [Google Scholar] [CrossRef]
- Zhen, Z.; Tang, W.; Wang, M.; Zhou, S.; Wang, H.; Wu, Z.; Hao, Z.; Li, Z.; Liu, L.; Xie, J. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy to Enhance Cytotoxic T Cell Infiltration and Tumor Control. Nano Lett. 2017, 17, 862–869. [Google Scholar] [CrossRef]
- Li, L.; Zhou, S.; Lv, N.; Zhen, Z.; Liu, T.; Gao, S.; Xie, J.; Ma, Q. Photosensitizer-Encapsulated Ferritins Mediate Photodynamic Therapy against Cancer-Associated Fibroblasts and Improve Tumor Accumulation of Nanoparticles. Mol. Pharm. 2018, 15, 3595–3599. [Google Scholar] [CrossRef]
- Yao, Q.; Cao, F.M.; Lang, M.; Feng, C.; Meng, X.; Zhang, Y.; Zhao, Y.; Wang, X.H. Rituxan Nanoconjugation Prolongs Drug/Cell Interaction and Enables Simultaneous Depletion and Enhanced Raman Detection of Lymphoma Cells. J. Mater. Chem. B 2017, 5, 5165–5175. [Google Scholar] [CrossRef]
- Franco, D.; Trusso, S.; Fazio, E.; Allegra, A.; Musolino, C.; Speciale, A.; Cimino, F.; Saija, A.; Neri, F.; Nicolò, M.S.; et al. Raman Spectroscopy Differentiates between Sensitive and Resistant Multiple Myeloma Cell Lines. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2017, 187, 15–22. [Google Scholar] [CrossRef]
- Fazio, E.; Trusso, S.; Franco, D.; Nicolò, M.S.; Allegra, A.; Neri, F.; Musolino, C.; Guglielmino, S.P. A Micro-Raman Spectroscopic Investigation of Leukemic U-937 Cells in Aged Cultures. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2016, 159, 21–29. [Google Scholar] [CrossRef] [PubMed]
- Lentini, G.; Fazio, E.; Calabrese, F.; De Plano, L.M.; Puliafico, M.; Franco, D.; Nicolò, M.S.; Carnazza, S.; Trusso, S.; Allegra, A.; et al. Phage-AgNPs Complex as SERS Probe for U937 Cell Identification. Biosens. Bioelectron. 2015, 74, 398–405. [Google Scholar] [CrossRef] [PubMed]
- Weber, A.N.R.; Bittner, Z.; Liu, X.; Dang, T.M.; Radsak, P.P.; Brunner, C. Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front. Immunol. 2017, 8, 1454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qiu, Q.; Li, C.; Song, Y.; Shi, T.; Luo, X.; Zhang, H.; Hu, L.; Yan, X.; Zheng, H.; Liu, M.; et al. Targeted Delivery of Ibrutinib to Tumor-Associated Macrophages by Sialic Acid-Stearic Acid Conjugate Modified Nanocomplexes for Cancer Immunotherapy. Acta Biomater. 2019, 92, 184–195. [Google Scholar] [CrossRef]
- Ettari, R.; Zappalà, M.; Grasso, S.; Musolino, C.; Innao, V.; Allegra, A. Immunoproteasome-Selective and Non-Selective Inhibitors: A Promising Approach for the Treatment of Multiple Myeloma. Pharmacol. Ther. 2018, 182, 176–192. [Google Scholar] [CrossRef] [PubMed]
- Allegra, A.; Sant’antonio, E.; Penna, G.; Alonci, A.; D’Angelo, A.; Russo, S.; Cannavò, A.; Gerace, D.; Musolino, C. Novel Therapeutic Strategies in Multiple Myeloma: Role of the Heat Shock Protein Inhibitors. Eur. J. Haematol. 2011, 86, 93–110. [Google Scholar] [CrossRef] [PubMed]
- Allegra, A.; Innao, V.; Allegra, A.G.; Pulvirenti, N.; Pugliese, M.; Musolino, C. Antitumorigenic Action of Nelfinavir: Effects on Multiple Myeloma and Hematologic Malignancies (Review). Oncol. Rep. 2020, 43, 1729–1736. [Google Scholar] [CrossRef] [PubMed]
- Allegra, A.; Penna, G.; Alonci, A.; Russo, S.; Greve, B.; Innao, V.; Minardi, V.; Musolino, C. Monoclonal Antibodies: Potential New Therapeutic Treatment against Multiple Myeloma. Eur. J. Haematol. 2013, 90, 441–468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caserta, S.; Innao, V.; Musolino, C.; Allegra, A. Immune Checkpoint Inhibitors in Multiple Myeloma: A Review of the Literature. Pathol. Res. Pract. 2020, 216, 153114. [Google Scholar] [CrossRef] [PubMed]
- Lopes, R.; Caetano, J.; Ferreira, B.; Barahona, F.; Carneiro, E.A.; João, C. The Immune Microenvironment in Multiple Myeloma: Friend or Foe? Cancers 2021, 13, 625. [Google Scholar] [CrossRef]
- Coquery, C.M.; Erickson, L.D. Regulatory Roles of the Tumor Necrosis Factor Receptor BCMA. Crit. Rev. Immunol. 2012, 32, 287–305. [Google Scholar] [CrossRef] [Green Version]
- Bae, J.; Samur, M.; Richardson, P.; Munshi, N.C.; Anderson, K.C. Selective Targeting of Multiple Myeloma by B Cell Maturation Antigen (BCMA)-Specific Central Memory CD8+ Cytotoxic T Lymphocytes: Immunotherapeutic Application in Vaccination and Adoptive Immunotherapy. Leukemia 2019, 33, 2208–2226. [Google Scholar] [CrossRef]
- Bae, J.; Parayath, N.; Ma, W.; Amiji, M.; Munshi, N.; Anderson, K.C. BCMA Peptide-Engineered Nanoparticles Enhance Induction and Function of Antigen-Specific CD8+ Cytotoxic T Lymphocytes against Multiple Myeloma: Clinical Applications. Leukemia 2020, 34, 210–223. [Google Scholar] [CrossRef]
- Alhallak, K.; Sun, J.; Wasden, K.; Guenthner, N.; O’Neal, J.; Muz, B.; King, J.; Kohnen, D.; Vij, R.; Achilefu, S.; et al. Nanoparticle T-Cell Engagers as a Modular Platform for Cancer Immunotherapy. Leukemia 2021, 35, 2346–2357. [Google Scholar] [CrossRef]
- Innao, V.; Allegra, A.G.; Musolino, C.; Allegra, A. New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era. Int. J. Mol. Sci. 2020, 21, 8902. [Google Scholar] [CrossRef]
- Allegra, A.; Innao, V.; Gerace, D.; Vaddinelli, D.; Musolino, C. Adoptive Immunotherapy for Hematological Malignancies: Current Status and New Insights in Chimeric Antigen Receptor T Cells. Blood Cells Mol. Dis. 2016, 62, 49–63. [Google Scholar] [CrossRef] [PubMed]
- Lichtman, E.I.; Du, H.; Shou, P.; Song, F.; Suzuki, K.; Ahn, S.; Li, G.; Ferrone, S.; Su, L.; Savoldo, B.; et al. Preclinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T cells for the Treatment of Acute Myeloid Leukemia. Clin. Cancer Res. 2021, 27, 3141–3153. [Google Scholar] [CrossRef] [PubMed]
- Vairy, S.; Garcia, J.L.; Teira, P.; Bittencourt, H. CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia. Drug Des. Dev. Ther. 2018, 12, 3885–3898. [Google Scholar] [CrossRef] [Green Version]
- Xiang, X.; He, Q.; Ou, Y.; Wang, W.; Wu, Y. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Front. Pharmacol. 2020, 11, 544754. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Wang, Y.; Yin, E.T.S.; Zhao, K.; Hu, Y.; Huang, H. A Giant Step Forward: Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Front. Med. 2020, 14, 711–725. [Google Scholar] [CrossRef] [PubMed]
- Yin, H.; Kauffman, K.J.; Anderson, D.G. Delivery Technologies for Genome Editing. Nat. Rev. Drug Discov. 2017, 16, 387–399. [Google Scholar] [CrossRef]
- Smith, T.T.; Stephan, S.B.; Moffett, H.F.; McKnight, L.E.; Ji, W.; Reiman, D.; Bonagofski, E.; Wohlfahrt, M.E.; Pillai, S.P.S.; Stephan, M.T. In Situ Programming of Leukaemia-Specific T Cells Using Synthetic DNA Nanocarriers. Nat. Nanotechnol. 2017, 12, 813–820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miller, M.A. Nanoparticles Improve Economic Mileage for CARs. Sci. Transl. Med. 2017, 9. [Google Scholar] [CrossRef]
- Smith, T.T.; Moffett, H.F.; Stephan, S.B.; Opel, C.F.; Dumigan, A.G.; Jiang, X.; Pillarisetty, V.G.; Pillai, S.P.S.; Wittrup, K.D.; Stephan, M.T. Biopolymers Codelivering Engineered T Cells and STING Agonists Can Eliminate Heterogeneous Tumors. J. Clin. Investig. 2017, 127, 2176–2191. [Google Scholar] [CrossRef]
- Dowaidar, M.; Abdelhamid, H.N.; Hällbrink, M.; Freimann, K.; Kurrikoff, K.; Zou, X.; Langel, Ü. Magnetic Nanoparticle Assisted Self-Assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. Sci. Rep. 2017, 7, 9159. [Google Scholar] [CrossRef] [Green Version]
- Tang, L.; Zheng, Y.; Melo, M.B.; Mabardi, L.; Castaño, A.P.; Xie, Y.Q.; Li, N.; Kudchodkar, S.B.; Wong, H.C.; Jeng, E.K.; et al. Enhancing T Cell Therapy Through TCR-Signaling-Responsive Nanoparticle Drug Delivery. Nat. Biotechnol. 2018, 36, 707–716. [Google Scholar] [CrossRef] [Green Version]
- Allegra, A.; Penna, G.; Innao, V.; Greve, B.; Maisano, V.; Russo, S.; Musolino, C. Vaccination of Multiple Myeloma: Current Strategies and Future Prospects. Crit. Rev. Oncol. Hematol. 2015, 96, 339–354. [Google Scholar] [CrossRef]
- Allegra, A.; Russo, S.; Gerace, D.; Calabrò, L.; Maisano, V.; Innao, V.; Musolino, C. Vaccination Strategies in Lymphoproliferative Disorders: Failures and Successes. Leuk. Res. 2015, 39, 1006–1019. [Google Scholar] [CrossRef] [PubMed]
- Van der Burg, S.H.; Arens, R.; Ossendorp, F.; van Hall, T.; Melief, C.J. Vaccines for Established Cancer: Overcoming the Challenges Posed by Immune Evasion. Nat. Rev. Cancer 2016, 16, 219–233. [Google Scholar] [CrossRef]
- Kouidhi, S.; Elgaaied, A.B.; Chouaib, S. Impact of Metabolism in on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment. Front. Immunol. 2017, 8, 270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ye, J.; Huang, X.; Hsueh, E.C.; Zhang, Q.; Ma, C.; Zhang, Y.; Varvares, M.A.; Hoft, D.F.; Peng, G. Human Regulatory T Cells Induce T-Lymphocyte Senescence. Blood 2012, 120, 2021–2031. [Google Scholar] [CrossRef]
- Han, H.D.; Byeon, Y.; Jang, J.H.; Jeon, H.N.; Kim, G.H.; Kim, M.G.; Pack, C.G.; Kang, T.H.; Jung, I.D.; Lim, Y.T.; et al. In Vivo Stepwise Immunomodulation Using Chitosan Nanoparticles as a Platform Nanotechnology for Cancer Immunotherapy. Sci. Rep. 2016, 6, 38348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kwong, B.; Liu, H.; Irvine, D.J. Induction of Potent Anti-tumor Responses while Eliminating Systemic Side Effects via Liposome-Anchored Combinatorial Immunotherapy. Biomaterials 2011, 32, 5134–5147. [Google Scholar] [CrossRef] [Green Version]
- Da Silva, C.G.; Peters, G.J.; Ossendorp, F.; Cruz, L.J. The Potential of Multi-Compound Nanoparticles to Bypass Drug Resistance in Cancer. Cancer Chemother. Pharmacol. 2017, 80, 881–894. [Google Scholar] [CrossRef] [Green Version]
- Makadia, H.K.; Siegel, S.J. Poly Lactic-Co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 2011, 3, 1377–1397. [Google Scholar] [CrossRef] [PubMed]
- LaVan, D.A.; McGuire, T.; Langer, R. Small-Scale Systems for In Vivo Drug Delivery. Nat. Biotechnol. 2003, 21, 1184–1191. [Google Scholar] [CrossRef]
- Dong, X.; Liang, J.; Yang, A.; Qian, Z.; Kong, D.; Lv, F. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy. ACS Appl. Mater. Interfaces 2019, 6, 4876–4888. [Google Scholar] [CrossRef]
- He, C.; Duan, X.; Guo, N.; Chan, C.; Poon, C.; Weichselbaum, R.R.; Lin, W. Core-Shell Nanoscale Coordination Polymers Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy. Nat. Commun. 2016, 7, 12499. [Google Scholar] [CrossRef] [Green Version]
- Chiang, C.S.; Lin, Y.J.; Lee, R.; Lai, Y.H.; Cheng, H.W.; Hsieh, C.H.; Shyu, W.C.; Chen, S.Y. Combination of Fucoidan-Based Magnetic Nanoparticles and Immunomodulators Enhances Tumour-Localized Immunotherapy. Nat. Nanotechnol. 2018, 13, 746–754. [Google Scholar] [CrossRef]
- Li, A.W.; Sobral, M.C.; Badrinath, S.; Choi, Y.; Graveline, A.; Stafford, A.G.; Weaver, J.C.; Dellacherie, M.O.; Shih, T.Y.; Ali, O.A.; et al. A Facile Approach to Enhance Antigen Response for Personalized Cancer Vaccination. Nat. Mater. 2018, 17, 528–534. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Li, W.A.; Choi, Y.; Lewin, S.A.; Verbeke, C.S.; Dranoff, G.; Mooney, D.J. Injectable, Spontaneously Assembling, Inorganic Scaffolds Modulate Immune Cells In Vivo and Increase Vaccine Efficacy. Nat. Biotechnol. 2015, 33, 64–72. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Wang, X.; Ito, A.; Tsuji, N.M. A Nanoscale Metal Organic Frameworks-Based Vaccine Synergises with PD-1 Blockade to Potentiate Anti-Tumour Immunity. Nat. Commun. 2020, 11, 3858. [Google Scholar] [CrossRef] [PubMed]
- Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [Google Scholar] [CrossRef]
- Reddy, S.T.; van der Vlies, A.J.; Simeoni, E.; Angeli, V.; Randolph, G.J.; O’Neil, C.P.; Lee, L.K.; Swartz, M.A.; Hubbell, J.A. Exploiting Lymphatic Transport and Complement Activation in Nanoparticle Vaccines. Nat. Biotechnol. 2007, 25, 1159–1164. [Google Scholar] [CrossRef] [PubMed]
- Zhu, G.; Zhang, F.; Ni, Q.; Niu, G.; Chen, X. Efficient Nanovaccine Delivery in Cancer Immunotherapy. ACS Nano 2017, 11, 2387–2392. [Google Scholar] [CrossRef]
- Reddy, S.T.; Rehor, A.; Schmoekel, H.G.; Hubbell, J.A.; Swartz, M.A. In Vivo Targeting of Dendritic Cells in Lymph Nodes with Poly (Propylene Sulfide) Nanoparticles. J. Control. Release 2006, 112, 26–34. [Google Scholar] [CrossRef] [PubMed]
- Carboni, E.; Tschudi, K.; Nam, J.; Lu, X.; Ma, A.W. Particle Margination and Its Implications on Intravenous Anticancer Drug Delivery. AAPS PharmSciTech 2014, 15, 762–771. [Google Scholar] [CrossRef] [Green Version]
- Gentile, F.; Chiappini, C.; Fine, D.; Bhavane, R.C.; Peluccio, M.S.; Cheng, M.M.; Liu, X.; Ferrari, M.; Decuzzi, P. The Effect of Shape on the Margination Dynamics of Non-Neutrally Buoyant Particles in Two-Dimensional Shear Flows. The Effect of Shape on the Margination Dynamics of Non-Neutrally Buoyant Particles in Two-Dimensional Shear Flows. J. Biomech. 2008, 41, 2312–2318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gratton, S.E.; Ropp, P.A.; Pohlhaus, P.D.; Luft, J.C.; Madden, V.J.; Napier, M.E.; DeSimone, J.M. The Effect of Particle Design on Cellular Internalization Pathways. Proc. Natl. Acad. Sci. USA 2008, 105, 11613–11618. [Google Scholar] [CrossRef] [Green Version]
- Sun, M.; Lee, J.; Chen, Y.; Hoshino, K. Studies of Nanoparticle Delivery with In Vitro Bio-Engineered Microtissues. Bioact. Mater. 2020, 5, 924–937. [Google Scholar] [CrossRef] [PubMed]
- Ke, Y.; Castro, C.; Choi, J.H. Structural DNA Nanotechnology: Artificial Nanostructures for Biomedical Research. Annu. Rev. Biomed. Eng. 2018, 20, 375–401. [Google Scholar] [CrossRef] [Green Version]
- Jacobs, L.; De Smidt, E.; Geukens, N.; Declerck, P.; Hollevoet, K. DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure. Mol. Ther. 2020, 28, 1068–1077. [Google Scholar] [CrossRef] [PubMed]
- Sun, W.; Ji, W.; Hall, J.M.; Hu, Q.; Wang, C.; Beisel, C.L.; Gu, Z. Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing. Angew. Chem. 2015, 54, 12029–12033. [Google Scholar] [CrossRef]
- Zhao, H.; Yuan, X.; Yu, J.; Huang, Y.; Shao, C.; Xiao, F.; Lin, L.; Li, Y.; Tian, L. Magnesium-Stabilized Multifunctional DNA Nanoparticles for Tumor-Targeted and pH-Responsive Drug Delivery. ACS Appl. Mater. Interfaces 2018, 10, 15418–15427. [Google Scholar] [CrossRef] [PubMed]
- Laurenzana, I.; Trino, S.; Lamorte, D.; Girasole, M.; Dinarelli, S.; De Stradis, A.; Grieco, V.; Maietti, M.; Traficante, A.; Statuto, T.; et al. Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. Int. J. Nanomed. 2021, 16, 3141. [Google Scholar] [CrossRef]
- Gu, W.; Meng, F.; Haag, R.; Zhong, Z. Actively Targeted Nanomedicines for Precision Cancer Therapy: Concept, Construction, Challenges and Clinical Translation. J. Control. Release 2021, 329, 676–695. [Google Scholar] [CrossRef]
- Huang, L.; Huang, J.; Huang, J.; Xue, H.; Liang, Z.; Wu, J.; Chen, C. Nanomedicine-A Promising Therapy for Hematological Malignancies. Biomater. Sci. 2020, 8, 2376–2393. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Ayala-Orozco, C.; Rauta, P.R.; Krishnan, S. The Application of Nanotechnology in Enhancing Immunotherapy for Cancer Treatment: Current Effects and Perspective. Nanoscale 2019, 11, 17157–17178. [Google Scholar] [CrossRef]
- Zhao, J.; Castranova, V. Toxicology of Nanomaterials Used in Nanomedicine. J. Toxicol. Environ. Health Part B 2011, 14, 593–632. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Mao, H.; Kawazoe, N.; Chen, G. Insight into the Interactions between Nanoparticles and Cells. Biomater. Sci. 2017, 5, 173–189. [Google Scholar] [CrossRef] [PubMed]
- Salatin, S.; Maleki Dizaj, A.; Khosroushahi, I. Effect of the Surface Modification, Size, and Shape on Cellular Uptake of Nanoparticles. Cell Biol. Int. 2015, 39, 881–890. [Google Scholar] [CrossRef]
- Martin, J.D.; Cabral, H.; Stylianopoulos, T.; Jain, R.K. Improving Cancer Immunotherapy Using Nanomedicines: Progress, Opportunities and Challenges. Nat. Rev. Clin. Oncol. 2020, 17, 251–266. [Google Scholar] [CrossRef]
- Lu, W.; Yao, J.; Zhu, X.; Qi, Y. Nanomedicines: Redefining Traditional Medicine. Biomed. Pharmacother. 2021, 134, 111103. [Google Scholar] [CrossRef]
Mechanism | Reference(s) |
---|---|
Better delivery of compounds with immunotherapeutic activity; increased biodistribution and tolerability | [35,36,37,38] |
Effects on tumor microenvironment | [61,62,63,70] |
Effects on activation and maturation of Dendritic cells | [70,71,72,73] |
Transport of adjuvant molecules | [75,76,77,78] |
Enhanced tumor cell localization | [80] |
Disease | Target and Mechanism | Compound | Ref. |
---|---|---|---|
Acute myeloid leukemia | Heme oxygenase 1 | Lipid-polymer hybrid nanoparticle (hNP) is loaded with tin mesoporphyrin (SnMP) | [84] |
Inhibition of kinases | Poly-lactide-co-glycolide core loaded with everolimus, albumin shell loaded with MAPK/STAT5 inhibitor, conjugated with monoclonal antibody against CD33 receptor. | [89] | |
Proliferation of CD8+ T cells against AML cells | Superparamagnetic iron-oxide nanoparticle core decorated with two humanized signaling proteins. HLA-A2-IgG4 hinge dimer molecules are conjugated to the core nanoparticle together with humanized anti-CD28 antibodies. | [90] | |
Acute lymphoblastic leukemia | Increased effect on CD19 cells (B leukemia cells) |
| [94] [95] |
Increased effect on CD3 cells (T leukemia cells) |
| [96] [97] | |
Increased effect on CD 19 cells (T leukemia cells) |
| [101] [102] | |
Lymphoma | Increased production of cytokines (IFN γ, IL-2) |
| [112] |
Increased antigen uptake | Silica-coated magnetic nanoparticles (MNPs@SiO2 (RITC)) with conjugated ovalbumin | [112] | |
Increased antigen-specific Th1 cell activity | Silica-coated magnetic nanoparticles (MNPs@SiO2 (RITC)) with conjugated ovalbumin. | [112] | |
Reduction of myeloid-derived suppressor cells | Dox-loaded PEG-Fmoc-NLG micelles. | [113] | |
Effect on Dendritic cells |
| [114] | |
Increased production of cytokines(IL-7) | OVA-bound nanoparticles encapsulating IL-7 | [116] | |
Increased CD4+/CD8+ T cells | Biotinylated CD20 and CD3 antibodies and ultra-small Fe3O4 nanoparticles with streptavidin and biotin. | [118] | |
Action on cancer-associated fibroblasts | scFv-Conjugated and ZnF16Pc-loaded ferritin nanoparticle | [132] | |
Protracted drug/cell contact | Rituxan conjugated to silver nanoparticles. | [133] | |
Increased capping of CD20 | Rituxan conjugated to silver nanoparticles. | [133] | |
Multiple Myeloma | Augment of specific memory CD0+ CTL response against MM cells | Heteroclitic BCMA72-80 [YLMFLLRKI] peptide-encapsulated liposome or poly (lactic-co-glycolic acid) nanoparticles. | [147] |
Effect on cytokine production | Heteroclitic BCMA72-80 [YLMFLLRKI] peptide-encapsulated liposome or poly (lactic-co-glycolic acid) nanoparticles. | [147] | |
Blocking of tumor antigen escape | Nanoparticle-based bispecific T-cell engagers (nanoBiTEs), decorated with anti-CD3 monoclonal antibodies (mAbs) targeting T cells, and mAbs targeting the cancer antigen. | [148] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Allegra, A.; Gioacchino, M.D.; Tonacci, A.; Petrarca, C.; Gangemi, S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials 2021, 11, 2792. https://doi.org/10.3390/nano11112792
Allegra A, Gioacchino MD, Tonacci A, Petrarca C, Gangemi S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials. 2021; 11(11):2792. https://doi.org/10.3390/nano11112792
Chicago/Turabian StyleAllegra, Alessandro, Mario Di Gioacchino, Alessandro Tonacci, Claudia Petrarca, and Sebastiano Gangemi. 2021. "Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective" Nanomaterials 11, no. 11: 2792. https://doi.org/10.3390/nano11112792